6 Needs context
Absence of mTORC1 in skeletal muscle causes muscle withering and wasting.
"So if you have no mTORC1, for example, in your muscles, you'd wither away and that would be a debilitating condition." (said at 0:04:48)
Preclinical animal models confirm that genetic ablation of essential mTORC1 components (such as Raptor) during skeletal muscle development and growth causes progressive muscular dystrophy, severe myopathy, and premature death. However, inducible deletion of mTORC1 signalling specifically in fully mature, sedentary adult mouse muscle does not immediately cause severe muscle wasting over several months, although it does impair muscle contractility, neuromuscular integrity, and translation machinery. Evidence is limited to animal knockout models.
- supports: Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes a… (Cell metabolism 2008) · cited 639x in the literature
"Here we show that the mTORC1 component raptor is critical for muscle function and prolonged survival... Raptor-deficient muscles become progressively dystrophic, are impaired in their oxidative capacity, and contain increased glycogen stores, but they express structural components indicative of oxidative muscle fibers." (abstract)
pubmedfull study (doi) - context: mTORC1 signalling is not essential for the maintenance of muscle mass and function in adul… (Journal of cachexia, sarcopenia and muscle 2020) · cited 35x in the literature
"Indeed, genetic inactivation of mTORC1 in developing and growing muscle causes atrophy resulting in a lethal myopathy... Nevertheless, no significant decrease in body and muscle mass or muscle fibre area was detected up to 5 months post-raptor depletion." (abstract, results)
pubmedfull study (doi) - supports: Inducible deletion of raptor and mTOR from adult skeletal muscle impairs muscle contractil… (The Journal of physiology 2022) · cited 14x in the literature
"Mammalian target of rapamycin plays a crucial role in the maintenance of muscle mass and functionality. We found that the loss of both mTOR and raptor results in contractile abnormalities, with severe muscle weakness and delayed relaxation following tetanic stimulation." (abstract, key points, passage verified)
pubmedfull study (doi)
mTORC1 in muscle tissue has a significantly higher affinity for leucine than mTORC1 in adipose tissue or hepatocytes.
"mTORC1 in muscle has a much higher affinity for leucine than mTORC1 in fat or in hepatocytes." (said at 0:07:30)
mTORC1 itself does not directly bind leucine; rather, intracellular leucine is sensed upstream by the Sestrin family of proteins (Sestrin1, Sestrin2, and Sestrin3), which regulate mTORC1 via the GATOR2-GATOR1-Rag GTPase pathway. Skeletal muscle predominantly expresses Sestrin1, which exhibits the highest binding affinity for leucine among the Sestrin isoforms, whereas other tissues such as the liver or adipose tissue rely on different isoform distributions (e.g., Sestrin2). Thus, while the underlying leucine-sensing machinery upstream of mTORC1 confers distinct tissue-specific sensitivity and affinity to leucine in skeletal muscle, the phrasing refers to upstream leucine sensors rather than the mTORC1 complex directly.
Cardiovascular and cerebrovascular disease, cancer, and neurodegenerative disease together account for approximately 75% of deaths.
"if you want to live longer, the name of the game is delaying the onset of the big three—the big three being the diseases that will kill 75% of us: cerebrovascular and cardiovascular, cancer, and neurodegenerative." (said at 0:15:29)
According to the Global Burden of Disease (GBD) Study and national vital statistics, all non-communicable diseases (NCDs) combined account for approximately 73.4% of all global deaths. Cardiovascular and cerebrovascular diseases (the leading cause of death globally and in developed countries) and neoplasms (cancer, the second leading cause) together account for roughly 45% to 50% of global mortality, while neurodegenerative disorders (such as Alzheimer's disease and other dementias) account for approximately 4% to 7% (higher in aging, high-income populations). While cardiovascular disease, cancer, and neurodegenerative diseases represent the vast majority of chronic adult mortality, reaching the ~75% threshold encompasses the broader category of all non-communicable diseases, which also includes chronic respiratory diseases, diabetes, and kidney diseases.
- context: Temporal Trends in Mortality in the United States, 1969-2013. (JAMA 2015) · cited 260x in the literature
"Between 1969 and 2013, the age-standardized death rate per 100,000 decreased from 1278.8 to 729.8 for all causes (42.9% reduction; 95% CI, 42.8%-43.0%), from 156.8 to 36.0 for stroke (77.0% reduction; 95% CI, 76.9%-77.2%), from 520.4 to 169.1 for heart disease (67.5% reduction; 95% CI, 67.4%-67.6%), from 65.1 to 39.2 for unintentional injuries (39.8% reduction; 95% CI, 39.3%-40.3%), from 198.6 to 163.1 for cancer (17.9% reduction; 95% CI, 17.5%-18.2%), and from 25.3 to 21.1 for diabetes (16.5% reduction; 95% CI, 15.4%-17.5%)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 c… (Lancet (London, England) 2018) · cited 8759x in the literature
"At the broadest grouping of causes of death (Level 1), non-communicable diseases (NCDs) comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5-74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional (CMNN) causes accounted for 18·6% (17·9-19·6), and injuries 8·0% (7·7-8·2)." (abstract, results, passage verified)
pubmedfull study (doi)
Research from the Gladstone Institutes shows APOE4 exhibits a dominant negative effect where the protein is cleaved and forms aggregates that activate microglia and trigger an inflammatory cascade in the brain.
"research—a lot of it coming out of UCSF Gladstone Institute—showing that in addition to a loss of function with APOE4, there's also a dominant negative effect. So apparently the APOE4, there's this two-amino-acid, you know, substitution, and structurally, if you look at the the structure of the protein, um, it starts to get cleaved. And so it itself starts to accumulate these like aggregates that it then, you know, keep you get more activated microglia and it keeps like spiraling out this whole inflammatory process in the brain." (said at 0:37:32)
Research from the Gladstone Institutes (e.g., Mahley, Huang, and colleagues) established that APOE4 undergoes neuron-specific proteolytic cleavage more readily than APOE3, generating C-terminal truncated fragments that exert a toxic gain-of-function effect in Alzheimer's disease models. However, the mechanism identified by Gladstone researchers involves these fragments entering the neuronal cytosol to disrupt the cytoskeleton, induce tau hyperphosphorylation, and cause direct neurotoxicity, rather than forming extracellular aggregates that drive microglial activation and neuroinflammation as described by the host. Additionally, the evidence for this proteolytic cleavage mechanism comes primarily from transgenic mouse models and in vitro systems.
Amgen conducted a Phase 2 trial of an IGF receptor antibody in advanced pancreatic cancer that failed despite reducing IGF levels at the receptor by 50%, and the antibody does not cross the blood-brain barrier.
"Amgen had a drug that was an IGF receptor antibody. It went into clinical trials, Phase 2 trials, in pancreatic cancer, advanced pancreatic cancer, and it failed. Now, it failed despite reducing IGF levels at the receptor by 50%. ... What's most interesting is that antibody does not cross the blood-brain barrier." (said at 0:46:43)
Amgen developed ganitumab (AMG 479), a monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), for advanced pancreatic cancer. However, the claim needs qualification: the randomized Phase 2 trial showed promising trends toward improved survival, leading to a large Phase 3 trial (the GAMMA trial), which ultimately failed to improve overall survival (median 7.0 vs 7.2 months). Additionally, while full-length monoclonal antibodies generally do not cross the blood-brain barrier, pancreatic adenocarcinoma is an abdominal tumor, making blood-brain barrier penetration irrelevant to the drug's therapeutic efficacy or failure in pancreatic cancer.
Astrocytes in the brain are glycolytic and metabolize glucose into lactate, which is then shuttled into neurons for mitochondrial energy metabolism.
"What's really interesting to me is the fact that neurons are actually mostly using lactate from astrocytes. Astrocytes are glycolytic, so the astrocytes are supporting cells in your brain, which are using glucose mostly. Are what using glucose to generate lactate. Lactate then gets shuttled into neurons, and then the neurons And the reason why neurons like that is because it's thermodynamically favorable" (said at 0:48:20)
The speaker is describing the Astrocyte-Neuron Lactate Shuttle (ANLS) hypothesis, first proposed by Pellerin and Magistretti. Under this model, astrocytes exhibit a predominantly glycolytic phenotype, metabolizing glucose or glycogen into lactate, which is then transported via monocarboxylate transporters into oxidative neurons to fuel mitochondrial metabolism. While extensively supported in biochemical, cell culture, and animal models, stating as an absolute fact that neurons 'mostly' rely on astrocyte-derived lactate overstates a debated model in neuroenergetics: substantial direct glucose uptake and oxidation by neurons also occur, and the quantitative dominance of lactate shuttling under resting versus activated conditions remains an active topic of research.
- supports: Sweet sixteen for ANLS. (Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2012) · cited 703x in the literature
"Thus, evidence for distinct metabolic phenotypes between neurons (mainly oxidative) and astrocytes (mainly glycolytic) have been provided by genomics and classical metabolic approaches. Moreover, it has become clear that astrocytes act as a syncytium to distribute energy substrates such as lactate to active neurones." (abstract, results, passage verified)
pubmedfull study (doi) - context: Brain Glucose Metabolism: Integration of Energetics with Function. (Physiological reviews 2019) · cited 896x in the literature
"Neuronal glucose oxidation exceeds that in astrocytes, but both rates increase in direct proportion to excitatory neurotransmission; signaling and metabolism are closely coupled at the local level. Exact details of neuron-astrocyte glutamate-glutamine cycling remain to be established, and the specific roles of glucose and lactate in the cellular energetics of these processes are debated. ... Shuttling of glucose- and glycogen-derived lactate from astrocytes to neurons during activation, neurotransmission, and memory consolidation are controversial topics for which alternative mechanisms are proposed." (abstract, results, passage verified)
pubmedfull study (doi)
29 Supported by research
Rapamycin inhibits a protein complex centered on the mammalian target of rapamycin (mTOR), a discovery made by David Sabatini as a PhD student at Johns Hopkins in 1993–1994.
"David Sabatini, as a PhD student at Hopkins in 1993-94, as a side project in a lab made the discovery that this thing, rapamycin, was actually working by inhibiting a protein complex of which target of rapamycin, as it became named, was the central piece." (said at 0:03:35)
David Sabatini, while an MD-PhD student in Solomon Snyder's laboratory at Johns Hopkins University, published the discovery of RAFT1 (rapamycin and FKBP12 target 1, subsequently recognized as mTOR) in 1994. The work demonstrated that rapamycin in complex with FKBP12 binds to and inhibits this large kinase complex homologous to the yeast TOR proteins.
mTOR forms two distinct cellular complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
"We now know today that it can form into two complexes: one is called mTOR complex 1 or mTORC1, and the other is mTOR complex 2, mTORC2." (said at 0:04:37)
The mechanistic target of rapamycin (mTOR) kinase functions in cells by assembling into two biochemically and functionally distinct multi-protein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), which differ in their subunit composition, upstream regulation, downstream substrates, and sensitivity to rapamycin.
IGF-1 signaling increases mTOR activity.
"IGF-1 actually increases mTOR activity. So they're not independent pathways." (said at 0:05:08)
Insulin-like growth factor 1 (IGF-1) signaling canonically activates mechanistic/mammalian target of rapamycin (mTOR) through the PI3K/Akt signaling cascade. Binding of IGF-1 to its receptor (IGF-1R) triggers downstream phosphoinositide 3-kinase (PI3K) and Akt activation, which relieves inhibition on mTORC1 and increases mTOR activity to promote protein synthesis and cell growth.
David Sabatini's lab at MIT published a paper in Science crystallizing and identifying the direct leucine sensor for mTORC1.
"David Sabatini and his group at MIT published a paper in Science that identified the amino acid sensor for mTORC1. Now, it's always been suspected what it was, which was leucine was the highest affinity, but in fact he's now crystallized that structure." (said at 0:06:10)
David Sabatini's laboratory identified Sestrin2 as a leucine sensor for the mTORC1 pathway and solved its crystal structure bound to leucine, published in back-to-back 2016 papers in Science. X-ray crystallography determined the 2.7 Å structure of Sestrin2 in complex with leucine, demonstrating the structural mechanism of leucine sensing by mTORC1.
Among the three branched-chain amino acids, leucine is the main driver of mTORC1 activation, while isoleucine and valine are virtually irrelevant.
"The branched-chain amino acids, there are three: leucine, isoleucine, and valine. It turns out that isoleucine and valine are virtually irrelevant; it's pretty much all leucine." (said at 0:07:12)
Mechanistic and cellular studies demonstrate that among the branched-chain amino acids (BCAAs), leucine is the primary driver of mechanistic target of rapamycin complex 1 (mTORC1) activation. Molecular sensors such as Sestrin2 exhibit high specificity for leucine, whereas isoleucine and valine fail to meaningfully stimulate key downstream mTORC1 signaling markers such as mTOR, 4E-BP1, and p70S6K1 phosphorylation under experimental conditions.
Sex hormone-binding globulin (SHBG) levels increase when insulin levels decrease.
"So sex hormone-binding globulin goes up when insulin goes down." (said at 0:11:00)
The statement is supported by interventional clinical trials and mechanistic studies. Insulin directly downregulates hepatic production of sex hormone-binding globulin (SHBG). Interventions that reduce circulating insulin concentrations—such as insulin-suppressing agents (e.g., diazoxide) or insulin-sensitizing treatments (e.g., metformin)—lead to significant increases in serum SHBG levels.
Carbohydrate restriction lowers insulin, which raises sex hormone-binding globulin (SHBG) and reduces free testosterone levels even if total testosterone is unchanged.
"There's always this complaint that free testosterone levels will drop, all things equal, in someone who restricts carbohydrates... all things equal, when insulin goes down, which is usually what happens when you restrict carbohydrates, sex hormone-binding globulin goes up. That means if you have no change in testosterone level or even estradiol level, free testosterone will go down." (said at 0:11:04)
Carbohydrate restriction typically reduces circulating insulin levels and hepatic lipogenesis, which leads to an increase in hepatic sex hormone-binding globulin (SHBG) synthesis. Because SHBG binds testosterone with high affinity, an increase in circulating SHBG concentrations reduces the free (unbound) fraction of testosterone even when total circulating testosterone levels remain unchanged. Controlled human trials evaluating ketogenic and very low-carbohydrate diets have confirmed that SHBG increases and free testosterone (or the free androgen index) decreases despite stable or minimally changed total testosterone.
Centenarians who live to 100 and beyond generally die of the same major chronic diseases as the general population (cardiovascular disease, cancer, neurodegenerative diseases), but at a delayed age.
"when you look at the people who live the longest, when you look at these people who live to 100 and beyond, for the most part they die of the exact same diseases as the rest of us schleps. They just get them later." (said at 0:15:29)
Evidence from large cohort studies of individuals with exceptional longevity, such as the New England Centenarian Study (NECS) and the Longevity Genes Project (LGP), demonstrates that centenarians generally suffer from the same major chronic diseases (such as cardiovascular disease, cancer, diabetes, and hypertension) as younger populations, but experience a marked delay in disease onset and a compression of morbidity. Studies show the onset of these major chronic conditions in long-lived cohorts occurs roughly 18 to 24 years later than in referent populations.
The common claim that bacterial cells in the human gut outnumber human cells by 10 to 1 is scientifically false.
"So the cells in the gut outnumber the cells in our body 10 to 1, that actually turns out to be false." (said at 0:21:30)
The statement is supported. A landmark quantitative analysis by Sender et al. (2016) re-evaluated historical estimates of bacterial and human cell counts in a reference 70-kg adult. They found approximately 3.8 × 10^13 bacterial cells (mostly in the colon) and 3.0 × 10^13 human cells, establishing that the bacteria-to-human cell ratio is approximately 1.3:1 (roughly 1:1) rather than the long-cited 10:1 ratio.
Clostridium difficile colitis can be successfully treated and reversed with fecal microbiota transplantation.
"So we're familiar with how C. diff colitis works and the reversal of C. diff with stool transplant, so those are remarkable examples." (said at 0:23:43)
A 2023 Cochrane Systematic Review of randomized controlled trials demonstrated that fecal microbiota transplantation (FMT) substantially increases the rate of resolution in patients with recurrent Clostridioides difficile infection compared to standard antibiotic therapy (risk ratio 1.92, 95% CI 1.36 to 2.71; number needed to treat = 3). Subsequent meta-analyses of randomized trials confirm that FMT is significantly superior to standard antibiotic treatment for resolving infection and preventing recurrences.
Decreasing insulin signaling in C. elegans through genetic manipulations can increase lifespan by up to 100%.
"When I first I start I was doing research at the Salk Institute in La Jolla before I went to graduate school, I was working on aging and specifically doing different, you know, genetic manipulations in C. elegans to look at the effects on aging. So insulin signaling was like obvious: decrease insulin signaling, you're going to, you know, increase this worm's lifespan by like up to 100%, which is like very profound." (said at 0:28:21)
The host's statement accurately reflects landmark findings in the genetics of aging in Caenorhabditis elegans. Mutations that downregulate the insulin/IGF-1-like signaling pathway (such as loss-of-function mutations in the insulin receptor homolog daf-2) extend the adult lifespan of C. elegans by more than 100% (doubling lifespan relative to wild-type worms), an effect that depends on the downstream FOXO transcription factor daf-16. Because this evidence is derived entirely from invertebrate model organisms, the certainty of evidence for organismal aging biology is rated very low.
The tumor suppressor protein p53 requires zinc to function properly.
"keeping cancer cells in check, like p53 is zinc-dependent proteins, magnesium, which is important for repairing damage, things like that." (said at 0:20:41)
The tumor suppressor protein p53 is a zinc-dependent transcription factor. Structural and biochemical research demonstrates that coordination of a single zinc ion in the DNA-binding core domain is essential for p53 to fold properly and bind target DNA sequences. In the absence or depletion of available zinc, p53 becomes structurally unstable at physiological temperatures, misfolds, and loses its tumor-suppressing activity.
- supports: p53 and Zinc: A Malleable Relationship. (Frontiers in molecular biosciences 2022) · cited 46x in the literature
"The conformation of p53 is unusually malleable: p53 binds zinc extremely tightly when folded, but is intrinsically unstable in the absence of zinc at 37°C. Whether the wild-type protein folds in the cell is largely determined by the concentration of available zinc. Consequently, zinc dysregulation in the cell as well as a large percentage of tumorigenic p53 mutations can cause p53 to lose zinc, misfold, and forfeit its tumor suppressing activity." (abstract, passage verified)
pubmedfull study (doi)
Fermentation of dietary fiber by gut microbiota generates short-chain fatty acids that regulate regulatory T cell (Treg) differentiation and hematopoiesis.
"looking at the role of fiber and certain types of fiber in fueling different species of bacteria in the gut and how those are generating short-chain fatty acids and other signaling molecules which are regulating hematopoiesis. They're regulating, you know, Tregs that we're making." (said at 0:27:51)
Preclinical experimental studies show that gut microbial fermentation of dietary fiber produces short-chain fatty acids (SCFAs), such as butyrate and propionate. These SCFAs regulate bone marrow hematopoiesis (such as macrophage and dendritic cell precursor generation) and promote the differentiation and expansion of regulatory T cells (Tregs). Because the evidence demonstrating these direct causal mechanisms is based on rodent and in vitro models, the certainty of evidence for humans is rated very low.
An APOE 3/4 genotype increases Alzheimer's disease hazard ratio by approximately 2x compared to APOE 3/3, while an APOE 4/4 genotype increases it by 10 to 20x.
"a 3/4 genotype just on a hazard ratio is about a 2x increase over the 3/3 in terms of Alzheimer's disease. A 4/4, of course, is anywhere from 10 to 20x depending on the series." (said at 0:30:55)
Large-scale epidemiological studies and landmark meta-analyses establish that carrying one APOE ε4 allele (APOE 3/4) confers an approximate 2- to 3-fold increased risk of Alzheimer's disease compared to the baseline APOE 3/3 genotype, whereas carrying two alleles (APOE 4/4) increases the risk by approximately 10- to 20-fold (with specific estimates varying depending on ancestry, age, sex, and cohort series).
- supports: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype an… (JAMA ) · cited 4677x in the literature
"Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon2/epsilon4 (OR=2.6, 95% CI=1.6-4.0), epsilon3/epsilon4 (OR=3.2, 95% CI=2.8-3.8), and epsilon4/epsilon4 (OR=14.9, 95% CI= 10.8-20.6)" (abstract, results, passage verified)
pubmed
Approximately 20% to 25% of the population has the APOE 3/4 genotype.
"the 3/4 3/4 is actually pretty big, it's about 20%, but the 3/3 is the largest one." (said at 0:31:25)
Large-scale genetic association studies and multi-ancestry meta-analyses of apolipoprotein E (APOE) genotype distributions demonstrate that APOE 3/3 is the most prevalent genotype across all major ancestral populations (accounting for roughly 55% to 65% of individuals), while the heterozygous APOE 3/4 genotype is the second most common genotype, found in approximately 15% to 25% of the general population depending on ancestral background (most commonly ~20% to 25% in European and certain African-descent cohorts).
- supports: APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. (JAMA neurology 2023) · cited 301x in the literature
"Apolipoprotein E (APOE)*2 and APOE*4 are, respectively, the strongest protective and risk-increasing, common genetic variants for late-onset Alzheimer disease (AD), making APOE status highly relevant toward clinical trial design and AD research broadly." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype an… (JAMA ) · cited 4677x in the literature
"Forty research teams contributed data on APOE genotype, sex, age at disease onset, and ethnic background for 5930 patients who met criteria for probable or definite AD and 8607 controls without dementia who were recruited from clinical, community, and brain bank sources." (abstract, methods, passage verified)
pubmed
Once corrected for LDL particle number or ApoB, the increased risk of cardiovascular disease from APOE 4/4 or 3/4 genotypes disappears.
"I think the evidence today suggests that once you normalize and correct for LDL particle number or ApoB, HOST: Yeah, it stops mattering." (said at 0:33:29)
Large prospective cohort studies and meta-analyses demonstrate that the increased risk of coronary heart disease associated with APOE4 carrier status (e.g., ε3/ε4 and ε4/ε4 genotypes) is primarily mediated by circulating atherogenic lipoproteins (such as LDL-C, LDL particles, and ApoB). In large observational cohorts, such as the EPIC-Norfolk study involving over 22,000 individuals, adjusting for atherogenic lipid profiles attenuated the association between APOE ε4 alleles and coronary heart disease risk such that it was no longer statistically significant.
- supports: Association of apolipoprotein E genotypes with lipid levels and coronary risk. (JAMA 2007) · cited 799x in the literature
"There were approximately linear relationships of apoE genotypes (when ordered epsilon2/epsilon2, epsilon2/epsilon3, epsilon2/epsilon4, epsilon3/epsilon3, epsilon3/epsilon4, epsilon4/epsilon4) with LDL-C and with coronary risk." (abstract, results, passage verified)
pubmedfull study (doi) - supports: APOE genotype, lipids, and coronary heart disease risk: a prospective population study. (Archives of internal medicine 2009) · cited 84x in the literature
"After additional adjustment for baseline levels of the ratio of low- to high-density lipoprotein cholesterol, the hazard ratios (and 95% confidence intervals) for *E2 and *E4 carriers were 0.97 (0.85-1.10) and 1.06 (0.97-1.15), respectively, when compared with *E3 homozygotes... In the largest prospective cohort study to date, CHD risk was not associated with APOE genotype after controlling for a variety of cardiovascular risk factors, particularly the ratio of low- to high-density lipoprotein cholesterol." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
The APOE2 allele is protective against cardiovascular disease, and an APOE 2/4 genotype has approximately the same cardiac risk as APOE 3/3.
"In cardiac disease, it does, and in cardiac disease, the 2/4 is about the same as the 3/3. The two and the four cancel." (said at 0:36:00)
Large-scale meta-analyses confirm that the APOE ε2 allele is associated with lower low-density lipoprotein cholesterol (LDL-C) and an approximate 18% to 20% lower risk of coronary heart disease compared to the reference ε3 allele or ε3/ε3 genotype. Furthermore, there is an approximately linear gene-dosage relationship across genotypes (ordered ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4) with LDL-C and coronary risk, meaning the cardioprotective effect of the ε2 allele and the atherogenic effect of the ε4 allele offset each other, yielding a cardiac risk in APOE 2/4 individuals that is comparable to the baseline APOE 3/3 genotype.
- supports: Association of apolipoprotein E genotypes with lipid levels and coronary risk. (JAMA 2007) · cited 799x in the literature
"There were approximately linear relationships of apoE genotypes (when ordered epsilon2/epsilon2, epsilon2/epsilon3, epsilon2/epsilon4, epsilon3/epsilon3, epsilon3/epsilon4, epsilon4/epsilon4) with LDL-C and with coronary risk." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Meta-analysis for the Association of Apolipoprotein E ε2/ε3/ε4 Polymorphism with Coronary … (Chinese medical journal 2015) · cited 26x in the literature
"Taken together, our meta-analysis supported a genetic association between APOE gene and CHD. ε4 increased the risk of CHD, whereas ε2 decreased the risk of CHD." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Alzheimer's disease is the only neurodegenerative disease on the top 10 causes of death list.
"it's the top it's the only neurodegenerative disease that's on the top 10 list of death." (said at 0:38:32)
According to mortality statistics from the Centers for Disease Control and Prevention (CDC) and national surveillance reports, Alzheimer's disease is consistently listed among the top 10 leading causes of death in the United States (ranking 6th or 7th, depending on the year). It is the only neurodegenerative disease in the top 10 list; other neurodegenerative conditions (such as Parkinson's disease or amyotrophic lateral sclerosis) rank lower.
Breast cancer accounts for 3% of deaths in women, all cancers combined account for 20% to 21%, and cardiac disease accounts for 22% to 23%.
"breast cancer accounts for 3% of deaths in women. ... Now, cancer in women, all cancers: 20, 21%. Cardiac disease: 22, 23%." (said at 0:39:02)
The speaker's figures accurately reflect United States mortality statistics compiled from national vital statistics and CDC WONDER data. In US women, cardiovascular disease (heart disease) is the leading cause of death, accounting for approximately 22% to 23% of total female deaths, closely followed by all cancers combined, which account for roughly 20% to 21% of deaths. Female breast cancer causes approximately 42,000 to 43,000 deaths annually out of roughly 1.5 million total female deaths, which is approximately 2.8% to 3.0% of all female deaths.
Smoking prevalence in the US population has declined from 45% to 18% over the past 40 years.
"smoking has gone from, you know, 45% of the population to 18% of the population. HOST: We reduced smoking in the US. GUEST1: In the US, that's right." (said at 0:41:33)
Published epidemiological surveillance data from national surveys in the United States confirm that adult cigarette smoking prevalence declined dramatically following the 1964 Surgeon General's report. Between 1965 and the early 2010s, adult smoking rates fell from approximately 42% (with rates of 51.9% in men and 33.9% in women in 1965) down to approximately 18% (21.6% in men and 16.5% in women by 2011, and ~18% overall in subsequent surveillance years).
In 40-day water-only fasting experiments conducted at Harvard, blood ketone levels rose to 5-7 mM and glucose stabilized at 3-4 mM (60-70 mg/dL) within approximately 7 days and remained there for the duration.
"there was a a lot of really interesting work back in the '60s done at Harvard with real fasting experiments, um, I mean 40-day fasts. So you'd have inpatient subjects given nothing but water and minerals for 40 days ... it turns out that within about 7 days you'll be at a ketone level of 5 to 7 millimolar, glucose will be down to 3 to 4 millimolar, which is, call it 60 to 70 milligrams per deciliter, and you will stay at those levels, you know, sort of for a very, you know, until at the end of the 40 days they're still in those levels." (said at 0:49:48)
The speaker accurately describes the classic prolonged starvation studies led by George F. Cahill Jr., Oliver E. Owen, and colleagues at Harvard Medical School (Peter Bent Brigham Hospital) in the late 1960s. In these experiments, obese inpatient subjects underwent 5 to 6 weeks (~40 days) of fasting receiving only water, vitamins, and mineral supplementation. Blood glucose dropped during the first few days and stabilized around 3–4 mM (~60–70 mg/dL), while ketone body levels (predominantly beta-hydroxybutyrate) rose to approximately 5–7 mM (reaching a plateau between 1 and 3 weeks) and remained stable for the duration of the fast, serving as the primary fuel for the brain.
- supports: Fuel metabolism in starvation. (Annual review of nutrition 2006) · cited 1329x in the literature
"The central role of insulin and the metabolism of free fatty acids, glycerol, glucose, lactate, and pyruvate, combined with indirect calorimetry, needed characterization in a near-steady state, namely prolonged starvation. This is the main topic of this chapter. Due to its use by brain, D-beta-hydroxybutyric acid not only has permitted man to survive prolonged starvation, but also may have therapeutic potential" (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Liver and kidney metabolism during prolonged starvation. (The Journal of clinical investigation 1969) · cited 873x in the literature
"This study quantifies the concentrations of circulating insulin, growth hormone, glucose, free fatty acids, glycerol, beta-hydroxybutyrate, acetoacetate, and alpha amino nitrogen in 11 obese subjects during prolonged starvation. The sites and estimated rates of gluconeogenesis and ketogenesis after 5-6 wk of fasting were investigated in five of the subjects. Blood glucose and insulin concentrations fell acutely during the 1st 3 days of fasting... The concentration of free fatty acids, beta-hydroxybutyrate, and acetoacetate did not reach a plateau until after 17 days." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Brain metabolism during fasting. (The Journal of clinical investigation 1967) · cited 1646x in the literature
"Catheterization of cerebral vessels in three obese patients undergoing 5-6 wk of starvation demonstrated that beta-hydroxybutyrate and acetoacetate replaced glucose as the predominant fuel for brain metabolism." (abstract, results, passage verified)
pubmedfull study (doi)
During prolonged fasting, brain glucose consumption drops from nearly 100% to roughly 40-50%, with the remainder supplied by ketone bodies.
"What's changing is the consumption by the neuron, which goes from at the initial state being about 100% glucose. ... but it would fall to maybe 40 or 50%, the the rest of it being made up by the combination of the ketones." (said at 0:51:20)
Classic human metabolic studies demonstrate that under non-fasting conditions, the human brain relies almost exclusively (~100%) on glucose for energy. During prolonged starvation (such as 5–6 weeks of fasting), blood ketone body levels rise significantly, and ketone bodies (beta-hydroxybutyrate and acetoacetate) replace glucose as the main energy substrate for the brain. Under these conditions, brain glucose consumption drops significantly (to roughly 30–50% of total cerebral energy requirements), with the remainder supplied by ketone bodies.
In animal models of traumatic brain injury, applying transcranial glutathione prevented over 50% of brain damage by sequestering reactive oxygen species.
"and this has been shown in animal models for TBI, that if you can prevent the... and this was done by, um, putting glutathione, uh, transcranially, which obviously is not going to happen, but anyways, um, they could prevent, like, over 50% of the damage because they were able to sequester the reactive oxygen species that start to cause all the damage and the inflammatory pathways that start to get, you know, out of control." (said at 0:56:18)
The speaker accurately described findings from a 2014 study in a murine closed-skull model of traumatic brain injury (TBI). Researchers demonstrated that transcranially applied glutathione crossed the skull bone, scavenged reactive oxygen species (ROS), modulated acute inflammatory cascades, and significantly attenuated meningeal and parenchymal cell death (reducing cell death by up to ~67%). Because these findings are restricted to preclinical animal models, the certainty of direct clinical translation is very low.
ApoB or LDL particle number is a superior biomarker to LDL cholesterol, non-HDL cholesterol, triglycerides, and HDL cholesterol for distinguishing cardiovascular disease risk.
"ApoB is the single best biomarker or LDL-P to distinguish your risk of cardiac disease. It trumps LDL cholesterol, it trumps non-HDL cholesterol, it trumps triglycerides, HDL cholesterol. Those things don't hold a candle to LDL particle number, ApoB." (said at 0:41:03)
Extensive meta-analytic and discordance evidence demonstrates that apolipoprotein B (apoB) and LDL particle number (LDL-P) are superior markers of cardiovascular disease risk compared with standard lipid measures including LDL cholesterol (LDL-C), non-HDL cholesterol (non-HDL-C), triglycerides, and HDL cholesterol. A 2025 systematic review of discordance analyses (15 studies, 593,354 participants) found that apoB outperformed LDL-C across all studies and proved significantly more accurate than non-HDL-C in identifying atherosclerotic cardiovascular disease risk in the majority of analyses. Furthermore, a meta-analysis of major randomized statin trials demonstrated that cardiovascular risk reduction was more closely related to reductions in apoB than to reductions in either LDL-C or non-HDL-C.
- supports: Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from… (Journal of the American Heart Association 2014) · cited 147x in the literature
"Compared within each trial, risk reduction per change in apoB averaged 21.6% (12.0%, 31.2%) greater than changes in LDL-C (P<0.001) and 24.3% (22.4%, 26.2%) greater than changes in non-HDL-C (P<0.001)... Using both a frequentist and Bayesian approach, relative risk reduction across 7 major placebo-controlled statin trials was more closely related to reductions in apoB than to reductions in either non-HDL-C or LDL-C." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. (Journal of clinical lipidology 2025) · cited 18x in the literature
"ApoB outperformed LDL-C in 9 of 9 studies whereas LDL P was superior to LDL-C in 2 of 3 comparisons. In 1 study, non-HDL-C was superior to apoB, in 1 study apoB and non-HDL-C were equivalent, whereas in 7 studies, apoB, overall, was a significantly more accurate marker of atherosclerotic cardiovascular disease risk than non-HDL-C. Discordance analysis provides robust evidence that apoB is a more accurate marker of cardiovascular risk than either LDL-C or non-HDL-C, notwithstanding these variables are highly intercorrelated." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
During physical exercise, circulating lactate crosses the blood-brain barrier and is taken up by the brain.
"Well, yeah, during exercise, I mean, but but it has been shown that lactate will cross over the blood-brain barrier during exercise as well." (said at 0:52:23)
Human physiological studies consistently demonstrate that during physical exercise, elevations in circulating arterial lactate drive lactate transport across the blood-brain barrier into the brain, where it is taken up and metabolized as an energy substrate.
Traumatic brain injury disrupts the ability of astrocytes to produce lactate in the brain.
"Um, but what's interesting is that TBI also disrupts astrocytes' ability to make lactate." (said at 0:55:23)
Preclinical models of traumatic brain injury (TBI) demonstrate that secondary metabolic impairment affects the astrocyte-neuron lactate shuttle (ANLS), compromising astrocytic glycolysis, lactate production, and lactate delivery to damaged neurons. In animal studies, astrocytic metabolic disruption exacerbates post-injury neuronal death and functional deficits, while restoring astrocytic glycolytic capacity or providing exogenous lactate mitigates neurodegeneration and cognitive impairment. Evidence is currently limited to preclinical and animal studies.
Matthew Vander Heiden, Lewis Cantley, and Craig Thompson published a paper in Science in 2009 addressing the metabolic role of the Warburg effect in cancer cells optimizing for cellular building blocks.
"Yeah, there's an amazing paper that Matthew Vander Heiden wrote in 2009 in Science with Lew Cantley and Craig Thompson on it that I was really... That was the time when I sort of shifted my point of view on that." (said at 0:57:58)
Matthew Vander Heiden, Lewis Cantley, and Craig Thompson published a landmark review in Science in May 2009 titled 'Understanding the Warburg effect: the metabolic requirements of cell proliferation' (PMID: 19460998). The paper argued that aerobic glycolysis in cancer cells and proliferating cells is adapted to support the uptake and incorporation of nutrients into biomass (nucleotides, amino acids, and lipids) rather than solely optimizing efficient ATP production.
Chemotherapy drugs kill rapidly proliferating normal cells in the body, such as hair and skin cells.
"chemotherapeutic drugs also kill normal cells, proliferating cells—you've got your hair, your skin, whatever is normally proliferating fast like a cancer cell." (said at 1:01:00)
The speaker's statement accurately describes a fundamental mechanism of conventional chemotherapy toxicity. Cytotoxic chemotherapeutic agents target rapidly dividing cells by interfering with cell cycle progression and DNA replication; consequently, healthy tissues with high basal rates of proliferation—such as hair follicle keratinocytes, the gastrointestinal epithelium, and bone marrow stem cells—are damaged alongside cancer cells, leading to characteristic side effects such as alopecia and mucositis.
- supports: Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is C… (Current oncology (Toronto, Ont.) 2023) · cited 80x in the literature
"In addition to killing cancer cells, chemotherapy is likely to damage rapidly proliferating healthy cells, including the hair follicle keratinocytes." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention. (Current oncology (Toronto, Ont.) 2024) · cited 19x in the literature
"However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA)." (abstract, background, passage verified)
pubmedfull study (doi)
Taking supplemental dietary antioxidants during cancer is dangerous because it blunts reactive oxygen species signaling that causes cancer cells to die.
"Um, it's also why taking supplemental dietary antioxidants when you have cancer is very dangerous, because you're blunting that whole signaling pathway, right? You're basically blunting all the reactive oxygen species that are usually signaling for your cells that are primed to die, for the cancer cells to die, and you're sequestering it. So, you know, and that's been shown." (said at 1:01:45)
The claim is supported by published clinical and mechanistic evidence. Cancer therapies such as radiation and many cytotoxic chemotherapies rely on generating high levels of reactive oxygen species (ROS) to trigger oxidative damage and apoptotic cell death in tumor cells. Systematic evaluation of the literature confirms that concurrent supplementation with dietary antioxidants can scavenge and neutralize these therapeutic ROS, blunting pro-apoptotic signaling and correlating with reduced treatment efficacy, higher rates of cancer recurrence, and increased mortality.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.